ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$13.08 USD
-0.50 (-3.68%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $13.10 +0.02 (0.15%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.08 USD
-0.50 (-3.68%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $13.10 +0.02 (0.15%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth F Momentum C VGM
Zacks News
Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) gains 3% on encouraging fiscal third-quarter 2024 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.
New Strong Buy Stocks for February 13th
by Zacks Equity Research
IKT, ETRN, ADMA, AFRM and ORC have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2023.
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the fourth quarter of 2023, partially offset by declining livestock product sales.
3 Medical Stocks to Buy as the Sector Continues to Grow
by Abhinab Dasgupta
HCA Healthcare (HCA), ADMA Biologics (ADMA) and Exelixis (EXEL) are three medical stocks that you can look into as the sector continues to sustain its end-of-the-year momentum.
Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Adma Biologics (ADMA) closed at $5.18 in the latest trading session, marking a -1.71% move from the prior day.
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Does Adma Biologics (ADMA) Have the Potential to Rally 31.55% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Adma Biologics (ADMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Adma Biologics (ADMA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Adma Biologics (ADMA) closed the most recent trading day at $5.23, moving -1.32% from the previous trading session.
Bristol Myers' (BMY) sBLAs for Breyanzi Get FDA Priority Tag
by Zacks Equity Research
Bristol Myers' (BMY) two sBLAs for Breyanzi in relapsed/refractory follicular lymphoma and relapsed/refractory mantle cell lymphoma receive FDA acceptance and priority review.
Best Momentum Stocks to Buy for January 31st
by Zacks Equity Research
ADMA, EKSO and IKT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 31, 2024.
Novo Nordisk (NVO) Q4 Earnings Top, GLP-1 Drugs Boost Sales
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected fourth-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.
New Strong Buy Stocks for January 31st
by Zacks Equity Research
ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.
Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Adma Biologics (ADMA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for January 24th
by Zacks Equity Research
ADMA, CM and HEAR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 24, 2023.
Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update
by Zacks Equity Research
Unicycive (UNCY) rises after the encouraging progress in the late-stage development of its lead candidate, OLC, for the hyperphosphatemia indication. The NDA submission is expected around mid-2024.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study
by Zacks Equity Research
Outlook (OTLK) stock rises after aligning with the FDA regarding the protocols of a non-inferiority study of ONS-5010 for AMD. The study is set to become the basis for BLA resubmission by 2024-end.
New Strong Buy Stocks for January 24th
by Zacks Equity Research
ADMA, PBPB, YPF, CM and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 24, 2023.
Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program
by Zacks Equity Research
Pharvaris (PHVS) rises 6% after the FDA lifts the clinical hold on the investigational candidate, deucrictibant, for the prophylactic treatment of HAE attacks.
Here's Why You Should Add Xenon (XENE) to Your Portfolio Now
by Zacks Equity Research
Xenon's (XENE) late-stage studies in epilepsy are progressing well. The company is also gearing up to initiate a late-stage study for the MDD indication in 2024.
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
by Zacks Equity Research
Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.
Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx
by Zacks Equity Research
Exelixis (EXEL) gets a favorable ruling from the European Patent Office in a lawsuit related to its oral oncology drug, Cabometyx.
Wall Street Analysts Predict a 27.09% Upside in Adma Biologics (ADMA): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 27.1% upside potential for Adma Biologics (ADMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.